HighVista Strategies LLC Buys New Shares in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

HighVista Strategies LLC acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,116 shares of the company's stock, valued at approximately $737,000.

Several other large investors have also bought and sold shares of CNTA. First Light Asset Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after acquiring an additional 1,778,515 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock valued at $35,518,000 after purchasing an additional 850,000 shares during the last quarter. FMR LLC increased its position in shares of Centessa Pharmaceuticals by 4.6% during the third quarter. FMR LLC now owns 2,916,494 shares of the company's stock worth $46,635,000 after buying an additional 129,300 shares during the period. Driehaus Capital Management LLC raised its stake in Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock worth $18,891,000 after buying an additional 987,997 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its holdings in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after buying an additional 1,625,000 shares during the period. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 1.0 %

NASDAQ:CNTA traded up $0.17 on Tuesday, hitting $17.12. The stock had a trading volume of 510,468 shares, compared to its average volume of 418,361. Centessa Pharmaceuticals plc has a 1 year low of $6.15 and a 1 year high of $18.74. The firm's fifty day simple moving average is $16.25 and its two-hundred day simple moving average is $12.78. The stock has a market cap of $2.26 billion, a P/E ratio of -11.19 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Activity

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the sale, the insider now owns 223,369 shares of the company's stock, valued at $3,350,535. The trade was a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.89, for a total value of $928,950.00. Following the completion of the transaction, the chief executive officer now owns 575,661 shares of the company's stock, valued at approximately $9,722,914.29. This trade represents a 8.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 375,128 shares of company stock valued at $6,148,522 in the last 90 days. Insiders own 11.59% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CNTA. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a report on Monday, September 16th. Finally, B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.